126
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Role of Lymphotoxin-α Gene Polymorphism in Hepatitis C Virus-Related Chronic Liver Disorders

, , , ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 1921-1930 | Published online: 25 May 2021

References

  • World Health Organization. Global hepatitis report 2017: web Annex B: WHO estimates of the prevalence and incidence of hepatitis C virus infection by WHO region, 2015.
  • World Health Organization. Hepatitis C virus fact sheet, WHO Report 164; 2013. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/in.dex.html. Accessed 58, 2021.
  • Pawlotsky JM, Negro F, Aghemo Aet al. EASL (European Association for the Study of the Liver) recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170–1218.32956768
  • Suruki RY, Mueller N, Hayashi K, et al. Host immune status and incidence of hepatocellular carcinoma among subjects infected with hepatitis C virus: a nested case-control study in Japan. Cancer Epidemiol Biomarkers Prev. 2006;15:2521–2525. doi:10.1158/1055-9965.EPI-06-048517164379
  • Karbalaei R, Piran M, Rezaei-Tavirani M, AsadzadehAghdaei H, Heidari MH. A systems biology analysis of protein-protein interaction of NASH and IBD based on comprehensive gene information. Gastroenterol Hepatol Bed Bench. 2017;10:194–201.29118935
  • Fletcher NF, Clark AR, Balfe P, McKeating JA. TNF superfamily members promote hepatitis C virus entry via an NF-kB and myosin light chain kinase-dependent pathway. J Gen Virol. 2017;98:405–412. doi:10.1099/jgv.0.00068927983476
  • Zekri AR, Hafez MM, Bahnassy AA, et al. Genetic profile of Egyptian hepatocellular-carcinoma associated with hepatitis C virus Genotype 4 by 15 K cDNA microarray: a preliminary study. BMC Res Notes. 2008;1:106. doi:10.1186/1756-0500-1-10618959789
  • Ghavami SB, Mohebbi SR, Karimi K, et al. Variants in two gene members of the TNF ligand superfamily and hepatitis C virus chronic disease. Gastroenterol Hepatol Bed Bench. 2018;11(Suppl.1):S66–S72.30774809
  • Posch PE, Cruz I, Bradshaw D, Medhekar BA. Novel polymorphisms and the definition of promoter ‘alleles’ of the tumor necrosis factor and lymphotoxin α loci: inclusion in HLA haplotypes. Genes Immun. 2003;4(8):547–558. doi:10.1038/sj.gene.636402314647194
  • Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119:651–665. doi:10.1182/blood-2011-04-32522522053109
  • Huang Y, Yu X, Wang L, et al. Four genetic polymorphisms of lymphotoxin-alpha gene and cancer risk: a systematic review and meta-analysis. PLoS One. 2013;8(12):e82519. doi:10.1371/journal.pone.008251924349304
  • Zhu A, Yang Z, Zhang H, Liu R. Associations of lymphotoxin-a (LTA) rs909253 A/G gene polymorphism, plasma level and risk of ankylosing spondylitis in a Chinese Han population. Sci Rep. 2020;10:1–6. doi:10.1038/s41598-020-57927-631913322
  • Goyal A, Kazim SN, Sakhuja P, Malhotra V, Arora N, Sarin SK. Association of TNF‐β polymorphism with disease severity among patients infected with hepatitis C virus. J Med Virol. 2004;72:60–65. doi:10.1002/jmv.1053314635012
  • Tsuchiya N, Tokushige K, Yamaguchi N, et al. Influence of TNF gene polymorphism in patients with acute and fulminant hepatitis. J Gastroenterol. 2004;39:859–866. doi:10.1007/s00535-004-1402-115565405
  • Suneetha PV, Sarin SK, Goyal A, Kumar GT, Shukla DK, Hissar S. Association between vitamin D receptor, CCR5, TNF-a and TNF-β gene polymorphisms and HBV infection and severity of liver disease. J Hepatol. 2006;44:856–863. doi:10.1016/j.jhep.2006.01.02816545485
  • Haybaeck J, Zeller N, Wolf MJ, et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell. 2009;16:295–308. doi:10.1016/j.ccr.2009.08.02119800575
  • Luedde T, Schwabe RFNF. κB in the liver-linking injury, fibrosis, and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:108–118. doi:10.1038/nrgastro.2010.21321293511
  • Newton JL, Harney SJ, Timms AE, et al. Dissection of class III major histocompatibility complex haplotypes associated with rheumatoid arthritis. Arthritis Rheum. 2004;50(7):2122–2129. doi:10.1002/art.2035815248209
  • Parks CG, Pandey JP, Dooley MA, et al. Genetic polymorphisms in tumor necrosis factor (TNF)-alpha and TNF-beta in a population-based study of systemic lupus erythematosus: associations and interaction with the interleukin-1alpha-889 C/T polymorphism. Hum Immunol. 2004;65:622–631. doi:10.1016/j.humimm.2004.03.00115219382
  • Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-α gene that are associated with susceptibility to myocardial infarction. Nat Genet. 2002;32(4):650–654. doi:10.1038/ng104712426569
  • Ramasawmy R, Fae KC, Cunha-Neto E, Mullar NG. Polymorphisms in the gene for lymphotoxin-α predispose to chronic Chagas cardiomyopathy. J Infect Dis. 2007;196(12):1836–1843. doi:10.1086/52365318190265
  • Messer G, Spengler U, Jung MC, et al. Polymorphic structure of the tumor necrosis factor (TNF) locus. An NcoI polymorphism in the first intron of the human TNF-β gene correlates with a variant amino acid in position 26 and a reduced level of TNF-β production. J Exp Med. 1991;173:209–215. doi:10.1084/jem.173.1.2091670638
  • Lovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–338. doi:10.1055/s-2007-100712210518312
  • Lupsor M, Badea R, Stefanescu H, et al. Performance of a new elastographic method (ARFI technology) compared to unidimensional transient elastography in the noninvasive assessment of chronic hepatitis C. Preliminary results. J Gastrointestin Liver Dis. 2009;18:303.19795024
  • Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the esophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646–649. doi:10.1002/bjs.18006008174541913
  • Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–470. doi:10.1053/jhep.2001.2217211172350
  • Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32–36. doi:10.1002/hep.2166917567829
  • El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–1273. doi:10.1053/j.gastro.2011.12.06122537432
  • Su CH, Lin Y, Cai L. Genetic factors, viral infection, other factors, and liver cancer: an update on current progress. Asian Pac J Cancer Prev. 2013;14:4953e60. doi:10.7314/APJCP.2013.14.9.495324175758
  • Yang MD, Hsu CM, Chang WS, et al. Tumor necrosis factor-a genotypes are associated with hepatocellular carcinoma risk in Taiwanese males, smokers, and alcohol drinkers. Anticancer Res. 2015;35:5417e23.26408704
  • Jeng JE, Wu HF, Tsai MF, et al. Independent and additive interaction between tumor necrosis factor β 252 polymorphisms and chronic hepatitis B and C virus Infection on risk and prognosis of hepatocellular carcinoma: a case-control study. Asian Pac J Cancer Prev. 2014;15:10209–10215. doi:10.7314/APJCP.2014.15.23.1020925556449
  • Cheng PN, Chiu HC, Chiu YC, Chen SC, Chen Y. Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community. PLoS One. 2018;13:0206947. doi:10.1371/journal.pone.0206947
  • Zhang N, Hartig H, Dzhagalov I, Draper D, He YW. The role of apoptosis in the development and function of T lymphocytes. Cell Res. 2005;15:749–769.16246265
  • Pan D, Zeng X, Yu H, et al. Role of cytokine gene polymorphisms on prognosis in hepatocellular carcinoma after radical surgery resection. Gene. 2014;544:32–40. doi:10.1016/j.gene.2014.04.04224768182
  • Mittal S, El-Serag HB. Epidemiology of HCC: consider the population. J Clin Gastroenterol. 2013;47:S2–S6. doi:10.1097/MCG.0b013e3182872f2923632345
  • Elgamal S, Ghafar AA, Ghoneem E, Elshaer M, Alrefai H, Elemshaty W. Characterization of patients with hepatocellular carcinoma on the way for early detection: one center experience. Egypt J Intern Med. 2019;30:231–238. doi:10.4103/ejim.ejim_29_18
  • Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe - a review. Euro Surveill. 2008;13:18880. doi:10.2807/ese.13.21.18880-en18761967
  • Osório FM, Lauar GM, Lima AS, Vidigal PV, Ferrari TC, Couto CA. Epidemiological aspects of hepatocellular carcinoma in a referral center of Minas Gerais, Brazil. Arq Gastroenterol. 2013;50:97–100. doi:10.1590/S0004-2803201300020001523903617
  • Shaker MK, Abdella HM, Khalifa MO, El Dorry AK. Epidemiological characteristics of hepatocellular carcinoma in Egypt: a retrospective analysis of 1313 cases. Liver Int. 2013;33:1601–1606. doi:10.1111/liv.1220923714212
  • Liu P, Xie SH, Hu S, et al. Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States. Oncotarget. 2017;8:68131–68137. doi:10.18632/oncotarget.1924528978103
  • Lee EY, Xuan Mai TT, Chang Y, Ki M. Trends of liver cancer and its major risk factors in Korea. Epidemiol Health. 2015;37:e2015016. doi:10.4178/epih/e201501625773443
  • Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42:S206–S214. doi:10.1016/S1590-8658(10)60507-520547305
  • Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48:1000–1007. doi:10.1016/j.jhep.2008.03.00918433919
  • Scheiner B, Kirstein M, Popp S, et al. Association of platelet count and mean platelet volume with overall survival in patients with cirrhosis and unresectable hepatocellular carcinoma. Liver Cancer. 2018;1–15. doi:10.1159/00048714829662829
  • Tsai JF, Chen SC, Lin ZY, et al. Interactive effects between Lymphotoxin α +252 polymorphism and habits of substance use on risk of hepatocellular carcinoma. Kaohsiung J Med Sci. 2017;33:334–338. doi:10.1016/j.kjms.2017.04.01028738973
  • Cagin YF, Atayan Y, Erdogan MA, Dagtekin F, Colak C. Incidence and clinical presentation of portal vein thrombosis in cirrhotic patients. Hepatobiliary Pancreat Dis Int. 2016;15:499–503. doi:10.1016/S1499-3872(16)60092-927733319
  • Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One. 2014;9:90929. doi:10.1371/journal.pone.0090929
  • Huang YC, Huang CF, Chang KC, et al. Community-based screening for hepatocellular carcinoma in elderly residents in a hepatitis B- and C-endemic area. J Gastroenterol Hepatol. 2011;26:129–134. doi:10.1111/j.1440-1746.2010.06476.x21175806
  • Everson GT, Shiffman ML, Hoefs JC, et al.; the HALT-C Trial Group. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2012;55:1019–1029. doi:10.1002/hep.2475222030902
  • Yilmaz Y, Erdal E, Atabey N, Brian IC. Platelets, microenvironment and hepatocellular carcinoma. Biochem Anal Biochem. 2016;5:281.
  • Yi SW, Choi JS, Yi JJ, Lee YH, Han KJ. Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status: a prospective cohort study in Korea. Cancer. 2018;124:2748–2757. doi:10.1002/cncr.3140629669170
  • McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011;15:223–243. doi:10.1016/j.cld.2011.03.00621689610
  • Sherman M. Primary malignant neoplasms of the liver. In: Dooley JS, Lok AS, Burroughs AK, Heathcote EJ, editors. Sherlock‟s Diseases of the Liver and Biliary System. 12th ed. Oxford: Blackwell Publishing Ltd; 2011:681–703.
  • Wang P, Kang D, Cao W, Wang Y, Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res. 2012;28:109–122. doi:10.1002/dmrr.1291
  • Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol. 2018;43:13–25. doi:10.1007/s00261-017-1209-1